New pill could slow Parkinson's progression in early stages

NCT ID NCT05424276

Completed Disease control Sponsor: ABLi Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called IkT-148009 (risvodetinib) in 137 people with early, untreated Parkinson's disease. Participants took one of three doses or a placebo daily for 12 weeks. The goal was to check safety and see if the drug improves movement and daily living skills. Results will help decide if larger, longer studies are worthwhile.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IkT-148009 (risvodetinib)
What this could lead to: If successful, this could point toward a new oral treatment option for early Parkinson's disease that may help control motor and non-motor symptoms without immediate need for other therapies.
What could go wrong: This is a small, 12-week Phase 2 trial with only 137 participants, so results may not apply to all Parkinson's patients. The drug may cause side effects or fail to show meaningful benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Neurologist

Boca Raton, Florida, 33486, United States
Neurology

Scottsdale, Arizona, 85258, United States
Neurology

Little Rock, Arkansas, 72205, United States
Neurology

Reseda, California, 91335, United States
Neurology

Stamford, Connecticut, 06905, United States
Neurology

Miami, Florida, 33136, United States
Neurology

Naples, Florida, 34105, United States
Neurology

Tampa, Florida, 33609, United States
Neurology

Tampa, Florida, 33613, United States
Neurology

Foxborough, Massachusetts, 02035, United States
Neurology

South Dartmouth, Massachusetts, 02747, United States
Neurology

Farmington Hills, Michigan, 48334, United States
Neurology

Golden Valley, Minnesota, 55427, United States
Neurology

West Long Branch, New Jersey, 07764, United States
Neurology

Durham, North Carolina, 27705, United States
Neurology

Raleigh, North Carolina, 27607, United States
Neurology

Columbus, Ohio, 43221, United States
Neurology

Tulsa, Oklahoma, 74136, United States
Neurology

Portland, Oregon, 97239, United States
Neurology

Port Royal, South Carolina, 29935, United States
Neurology

Memphis, Tennessee, 38137, United States
Neurology

Nashville, Tennessee, 37232, United States
Neurology

Frisco, Texas, 75035, United States
Neurology

Houston, Texas, 77030, United States
Neurology

Round Rock, Texas, 78681, United States
Neurology

Kirkland, Washington, 98034, United States
Neurology

Madison, Wisconsin, 53705, United States
Neurology

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.